Our results describe a slight, albeit not significant, benefit for early-stage HCC patients with a high expression of SIRT-3 in line with Zhang and colleagues [12], and a significant benefit for those with a high nuclear HIF-1α expression contrary to what is reported in the literature [14,30,31]. Here, SIRT3 is linked to hepatocellular carcinoma.